Erasca, Inc. (ERAS): Price and Financial Metrics

Erasca, Inc. (ERAS): $2.11

0.18 (-7.86%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add ERAS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#85 of 360

in industry

ERAS Price/Volume Stats

Current price $2.11 52-week high $3.38
Prev. close $2.29 52-week low $1.51
Day low $2.08 Volume 584,400
Day high $2.28 Avg. volume 804,685
50-day MA $2.08 Dividend yield N/A
200-day MA $2.23 Market Cap 319.65M

ERAS Stock Price Chart Interactive Chart >


Erasca, Inc. (ERAS) Company Bio


Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.


ERAS Latest News Stream


Event/Time News Detail
Loading, please wait...

ERAS Latest Social Stream


Loading social stream, please wait...

View Full ERAS Social Stream

Latest ERAS News From Around the Web

Below are the latest news stories about ERASCA INC that investors may wish to consider to help them evaluate ERAS as an investment opportunity.

3 Penny Stocks You’ll Regret Not Buying Soon: December Edition

Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios.

Matthew Farley on InvestorPlace | December 20, 2023

Erasca Co-Founder Acquires 3.2% More Stock

Those following along with Erasca, Inc. ( NASDAQ:ERAS ) will no doubt be intrigued by the recent purchase of shares by...

Yahoo | December 13, 2023

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused

Yahoo | December 11, 2023

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in recurrent GBM Extended cash runway to H1 2026 following strategic prioritization of programs SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company sin

Yahoo | November 28, 2023

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driv

Yahoo | November 9, 2023

Read More 'ERAS' Stories Here

ERAS Price Returns

1-mo -1.40%
3-mo N/A
6-mo -13.17%
1-year -27.74%
3-year N/A
5-year N/A
YTD -0.94%
2023 -50.58%
2022 -72.34%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!